Neostem Files Patent Application For Cosmetic Stem Cell Face Lift Technology And Expands Stem Cell C

< BACK TO INFORMATION TECHNOLOGY starstarstarstarstar   Science - Information Technology Press Release
7th May 2009, 12:17am - Views: 833





Science Information Technology NeoStem, Inc. 1 image







NeoStem Files Patent Application for Cosmetic Stem Cell Face Lift Technology and

Expands Stem Cell Collection Network into New Jersey


NEW YORK, May 6 /PRNewswire-AsiaNet/ --


    NeoStem, Inc. (NYSE Amex: NBS), which is pioneering the pre-disease

collection, processing and long-term storage of adult stem cells for future

medical need, has filed a patent application claiming the proprietary stem

cell technology of Vincent C. Giampapa, M.D., F.A.C.S. relating to cosmetic

facial rejuvenation, which NeoStem first licensed in February 2009.


    The newest adult stem cell collection center in the NeoStem network,

located at the Giampapa Institute for Anti-Aging Medical Therapy in

Montclair, New Jersey, has received, from the state of New Jersey Department

of Health and Senior Services, a blood bank license for autologous peripheral

blood stem cell collection. This allows the center to open and commence

operations, and together with the patent application will serve to

significantly advance NeoStem's leadership in the anti-aging and regenerative

medicine arena.


    Dr. Giampapa, director of the Giampapa Institute for Anti-Aging Medical

Therapy, is a board-certified plastic reconstructive surgeon and Assistant

Clinical Professor of Plastic and Reconstructive Surgery at the University of

Medicine and Dentistry of New Jersey and is one of the first certified

anti-aging medical physicians in the world. His research and technology

comprise a non-surgical procedure for complete facial rejuvenation that

involves injecting pluripotent cells, including stem cells, into the skin of

individuals whose skin has lost its firmness and texture due to age. The

pluripotent cells stimulate the growth of various cells in the skin, leading

to the restoration of the skin's firmness and texture. The procedure can be

accomplished under local anesthesia in an office setting and typically

requires only a week of recovery time.


    "NeoStem is very focused on acquiring technologies related to stem cell

therapies," stated Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer.

"We are especially delighted to strengthen our relationship with Dr.

Giampapa, as anti-aging technology is one of our key pursuits. Filing a

patent for stem cell facial rejuvenation technology, while launching a new

NeoStem collection center at the Giampapa Institute, creates a particularly

advantageous situation for NeoStem. Just last week, the Food and Drug

Administration announced that Botox and similar anti-wrinkle drugs must now

carry "black box" warning labels explaining the potential of these materials

to spread from the injection site to distant parts of the body, creating

possible problems with swallowing or breathing. People worldwide can be

expected to seek safer alternatives and NeoStem believes that the use of

autologous stem cell procedures ("Your Cells for Your Use") may in fact be

that effective, safe and non-invasive alternative."


    About NeoStem, Inc.

    NeoStem is developing a network of adult stem cell collection centers

that are focused on enabling people to donate and store their own

(autologous) stem cells when they are young and healthy for their personal

use in times of future medical need. The Company has also entered into

research and development through the acquisition of a worldwide exclusive

license to technology to identify and isolate VSELs (very small

embryonic-like stem cells), which have been shown to have several physical

characteristics that are generally found in embryonic stem cells. The Company

Science Information Technology NeoStem, Inc. 2 image

is also pursuing other technologies to advance it position in the field of

stem cell tissue regeneration.




    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning

of the Private Securities Litigation Reform Act of 1995. Forward-looking

statements reflect management's current expectations, as of the date of this

press release, and involve certain risks and uncertainties. The Company's

actual results, including the success of the collection centers in its

network and whether the patent application described in this press release

will issue, could differ materially from those anticipated in these

forward-looking statements as a result of various factors. Factors that could

cause future results to materially differ from the recent results or those

projected in forward-looking statements include the "Risk Factors" described

in the Company's Annual Report on Form 10-K for its fiscal year ended

December 31, 2008 and the Company's other periodic filings with the

Securities and Exchange Commission. The Company's further development is

highly dependent on future medical and research developments and market

acceptance, which is outside its control.


    Contact:

      NeoStem, Inc.

      Robin Smith, Chief Executive Officer

      T: 212-584-4180

      E: rsmith@neostem.com

      www.neostem.com


SOURCE: NeoStem, Inc.


    CONTACT: Robin Smith

             Chief Executive Officer of NeoStem, Inc.

             +1-212-584-4180

             rsmith@neostem.com

             (NBS)



Translations:

   Chinese - Traditional (http://asianetnews.net/Download.asp?ID=125079)






To view this and other AsiaNet releases please visit http://www.asianetnews.net






news articles logo NEWS ARTICLES
Contact News Articles |Remove this article